GSK suffers another R&D setback, axing ulcerative colitis drug trial

GSK suffers another R&D setback, axing ulcerative colitis drug trial

Source: 
Pharmaforum
snippet: 

GlaxoSmithKline has suffered another research setback after it axed a phase 2 trial of an anti-LAG3 drug in patients with ulcerative colitis, following a major disappointment with a key lung cancer drug last week.